Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects

Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1

(2010) Stefan Oswald et al.   Pharmacogenetics and Genomics

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin

(2009) M V Tzvetkov et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors

(2009) R. L. Oostendorp et al.   DRUG METABOLISM AND DISPOSITION

Identification of Human Metabolites of (-)-N- -4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, and Investigation of the Transporter-Mediated Renal and Hepatic Excretion of These Metabolites

(2009) K.-i. Umehara et al.   DRUG METABOLISM AND DISPOSITION

In vitroevidence for the role of OATP and OCT uptake transporters in drug–drug interactions

(2009) Jürgen Kindla et al.   Expert Opinion on Drug Metabolism & Toxicology

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

(2009) Ichiro Ieiri et al.   Expert Opinion on Drug Metabolism & Toxicology

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

(2009) Anne T. Nies et al.   HEPATOLOGY

Genome-wide association meta-analysis for total serum bilirubin levels

(2009) A. D. Johnson et al.   HUMAN MOLECULAR GENETICS

Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia

(2009) Serena Sanna et al.   HUMAN MOLECULAR GENETICS

Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response

(2009) Edward B. Mougey et al.   Pharmacogenetics and Genomics

Impact of regulatory polymorphisms in organic anion transporter genes in the human liver

(2009) Masayo Aoki et al.   Pharmacogenetics and Genomics

Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans

(2009) Xiaoqiang Xiang et al.   Pharmacogenetics and Genomics

Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1

(2008) Tomoko Sato et al.   BIOCHEMICAL PHARMACOLOGY

The effect ofSLCO1B1polymorphism on repaglinide pharmacokinetics persists over a wide dose range

(2008) Annikka Kalliokoski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia

(2008) Kazuma Kiyotani et al.   CANCER SCIENCE

Interaction of Imatinib with Human Organic Ion Carriers

(2008) S. Hu et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

(2008) Pertti J Neuvonen et al.   CLINICAL PHARMACOKINETICS

Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1

(2008) I. Bachmakov et al.   DIABETES

Relevance of the Organic Cation Transporters 1 and 2 for Antiretroviral Drug Therapy in Human Immunodeficiency Virus Infection

(2008) N. Jung et al.   DRUG METABOLISM AND DISPOSITION

Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

(2008) Annikka Kalliokoski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism

(2008) Suttasinee Suwannakul et al.   JOURNAL OF HUMAN GENETICS

Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine

(2008) S. Matsushima et al.   MOLECULAR PHARMACOLOGY

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

(2008) Annikka Kalliokoski et al.   Pharmacogenetics and Genomics

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15

(2008) Jian Wei Deng et al.   Pharmacogenetics and Genomics

Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy

(2008) Philippe Couvert et al.   PHARMACOGENOMICS

Polymorphism in human organic cation transporters and metformin action

(2008) Hiroshi Takane et al.   PHARMACOGENOMICS

Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1–3in vitroand implications for drug–drug interactions

(2008) K.-I. Umehara et al.   XENOBIOTICA

Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer

(2007) Ji-Youn Han et al.   LUNG CANCER